Fabrication of novel and context-specific human liver cell lines using synthetic genome engineering for pharmaceutical applications.

Project Details


This project will utilize advances in CRISPR technology and synthetic biological engineering technologies available at the University of Edinburgh (Institute for BioEngineering: IBioE), to develop advanced derivatives of the widely-used human liver cell line HepaRG, for pharmaceutical applications (heparg.com). This will be achieved through a collaborative effort involving IBioE, Biopredic International (who owns the exclusive world distribution license for the HepaRG line); and Synthego.com, who provide precision tools for CRISPR genome engineering. Each of these areas will be pushed well beyond the state-of-the-art and validated using robust testing protocols. HepaRG cells are considered the most realistic surrogate for scarce, unstable, and expensive primary human hepatocytes (PHHs) for preclinical drug discovery and development. HepaRG cells have similar functionality to PHHs, and express key components of the liver’s drug metabolic machinery i.e. the Cytochrome P450 (CYP450) protein system.
Effective start/end date1/02/1831/10/18


Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.